[
  {
    "ts": "2026-02-02T02:15:51+00:00",
    "headline": "Dow Jones Futures: Silver Rebounds After Crash; Google, AMD, Amazon, Palantir Due",
    "summary": "Bitcoin's woes signals a further risk-off shift after Indexes tested support and silver dived. Google, AMD, Lilly, Amazon loom. Google, AMD, Eli Lilly, Amazon and Palantir earnings loom.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-risk-off-shift-google-amd-amazon-palantir-lilly/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "3963c6fb-920c-30c6-9b2b-676e9585bc6e",
      "content": {
        "id": "3963c6fb-920c-30c6-9b2b-676e9585bc6e",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Silver Rebounds After Crash; Google, AMD, Amazon, Palantir Due",
        "description": "",
        "summary": "Bitcoin's woes signals a further risk-off shift after Indexes tested support and silver dived. Google, AMD, Lilly, Amazon loom. Google, AMD, Eli Lilly, Amazon and Palantir earnings loom.",
        "pubDate": "2026-02-02T02:15:51Z",
        "displayTime": "2026-02-02T02:15:51Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3963c6fb-920c-30c6-9b2b-676e9585bc6e/dow-jones-futures-silver.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/630529e8a1faf673467f584d5c177982",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IiX8nCunCpbELdj7lJ3Xqw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/630529e8a1faf673467f584d5c177982.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YxEo1yZt5nPx1YSvL.YfVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/630529e8a1faf673467f584d5c177982.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-risk-off-shift-google-amd-amazon-palantir-lilly/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DIS"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "SI=F"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "ORCL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T03:57:55+00:00",
    "headline": "Dow Jones Futures Fall, Bitcoin Dives To Lowest Since 2024; Google, AMD, Amazon, Palantir Due",
    "summary": "Futures fell and Bitcoin tumbled after Indexes tested support and silver dived Friday. Google, AMD, Lilly, Amazon, Palantir loom.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-risk-off-shift-google-amd-amazon-palantir-lilly/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "3963c6fb-920c-30c6-9b2b-676e9585bc6e",
      "content": {
        "id": "3963c6fb-920c-30c6-9b2b-676e9585bc6e",
        "contentType": "STORY",
        "title": "Dow Jones Futures Fall, Bitcoin Dives To Lowest Since 2024; Google, AMD, Amazon, Palantir Due",
        "description": "",
        "summary": "Futures fell and Bitcoin tumbled after Indexes tested support and silver dived Friday. Google, AMD, Lilly, Amazon, Palantir loom.",
        "pubDate": "2026-02-02T03:57:55Z",
        "displayTime": "2026-02-02T03:57:55Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3963c6fb-920c-30c6-9b2b-676e9585bc6e/dow-jones-futures-fall-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/630529e8a1faf673467f584d5c177982",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IiX8nCunCpbELdj7lJ3Xqw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/630529e8a1faf673467f584d5c177982.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YxEo1yZt5nPx1YSvL.YfVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/630529e8a1faf673467f584d5c177982.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-risk-off-shift-google-amd-amazon-palantir-lilly/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DIS"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "ORCL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T07:13:41+00:00",
    "headline": "Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week",
    "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report this week, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-02-2026/card/jobs-report-big-tech-and-pharma-earnings-what-to-watch-this-week-zdM5ezszjvecNTLdBqHM?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "1521e877-0a57-3347-a784-96c8c490471a",
      "content": {
        "id": "1521e877-0a57-3347-a784-96c8c490471a",
        "contentType": "STORY",
        "title": "Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week",
        "description": "",
        "summary": "Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report this week, following on the heels of disappointing results from Microsoft that helped send software stocks tumbling.",
        "pubDate": "2026-02-02T07:13:41Z",
        "displayTime": "2026-02-02T07:13:41Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1521e877-0a57-3347-a784-96c8c490471a/jobs-report-big-tech-and.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/cf6a54be63658dfd69d6c7ba035c59ea",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SZUiVZZ42KpjrK_ZQ3c.Ng--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/cf6a54be63658dfd69d6c7ba035c59ea.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FKUglArkR9ZcBRUnP.OtQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/cf6a54be63658dfd69d6c7ba035c59ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-02-2026/card/jobs-report-big-tech-and-pharma-earnings-what-to-watch-this-week-zdM5ezszjvecNTLdBqHM?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "DIS"
            },
            {
              "symbol": "NXPI"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "TSN"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "SAN"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MDLZ"
            },
            {
              "symbol": "PEP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T09:16:52+00:00",
    "headline": "ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs",
    "summary": "ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 11 Best Performing Stocks in the Last 12 Months. For the past couple of months, speculation has arisen that Eli Lilly, an American multinational pharmaceutical company, is pursuing a potential acquisition of ABIVAX Société Anonyme (NASDAQ:ABVX). However, on January 20, 2026, ABIVAX’s CEO Marc De Garidel dismissed […]",
    "url": "https://finance.yahoo.com/news/abivax-soci-t-anonyme-abvx-091652316.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "6a5937d7-aa17-3892-890b-33f5cab8c60c",
      "content": {
        "id": "6a5937d7-aa17-3892-890b-33f5cab8c60c",
        "contentType": "STORY",
        "title": "ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs",
        "description": "",
        "summary": "ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the 11 Best Performing Stocks in the Last 12 Months. For the past couple of months, speculation has arisen that Eli Lilly, an American multinational pharmaceutical company, is pursuing a potential acquisition of ABIVAX Société Anonyme (NASDAQ:ABVX). However, on January 20, 2026, ABIVAX’s CEO Marc De Garidel dismissed […]",
        "pubDate": "2026-02-02T09:16:52Z",
        "displayTime": "2026-02-02T09:16:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/89c0b31c8a49a4b2c6733fddd0910df8",
          "originalWidth": 4069,
          "originalHeight": 2713,
          "caption": "ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sunxx6hqXfBWKrzfL3htQg--~B/aD0yNzEzO3c9NDA2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/89c0b31c8a49a4b2c6733fddd0910df8.cf.webp",
              "width": 4069,
              "height": 2713,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2LdiLb4t.zgVLda0bwZNgg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/89c0b31c8a49a4b2c6733fddd0910df8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abivax-soci-t-anonyme-abvx-091652316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abivax-soci-t-anonyme-abvx-091652316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "AAVXF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T09:11:17+00:00",
    "headline": "Eli Lilly Expands Obesity And Gene Programs As Valuation Pulls Back",
    "summary": "Eli Lilly (NYSE:LLY) is committing $3.5b to build a new Pennsylvania facility to produce next generation injectable weight loss drugs. The company also announced a research collaboration with Seamless Therapeutics focused on gene editing approaches for hearing loss. A separate collaboration with Repertoire Immune Medicines aims to develop tolerizing therapies for autoimmune diseases. Eli Lilly enters this news cycle with a current share price of $1,037.15 and a 5 year return of 431.1%. The...",
    "url": "https://finance.yahoo.com/news/eli-lilly-expands-obesity-gene-091117318.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a473f25c-589a-34c9-9f40-96ce6e176db7",
      "content": {
        "id": "a473f25c-589a-34c9-9f40-96ce6e176db7",
        "contentType": "STORY",
        "title": "Eli Lilly Expands Obesity And Gene Programs As Valuation Pulls Back",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) is committing $3.5b to build a new Pennsylvania facility to produce next generation injectable weight loss drugs. The company also announced a research collaboration with Seamless Therapeutics focused on gene editing approaches for hearing loss. A separate collaboration with Repertoire Immune Medicines aims to develop tolerizing therapies for autoimmune diseases. Eli Lilly enters this news cycle with a current share price of $1,037.15 and a 5 year return of 431.1%. The...",
        "pubDate": "2026-02-02T09:11:17Z",
        "displayTime": "2026-02-02T09:11:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-obesity-gene-091117318.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-expands-obesity-gene-091117318.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T10:08:02+00:00",
    "headline": "Did Lilly's $3.5 Billion Retatrutide Plant Just Recast Eli Lilly's (LLY) Obesity Investment Narrative?",
    "summary": "Eli Lilly and Company recently announced plans to invest more than US$3.50 billion in a new Lehigh Valley, Pennsylvania manufacturing facility that will produce next-generation injectable weight-loss medicines, including the investigational therapy retatrutide, with operations targeted for 2031. By pairing this build-out with advanced AI-enabled manufacturing and a growing network of U.S. plants, Lilly is signaling a long-term commitment to scaling obesity treatments and reinforcing domestic...",
    "url": "https://finance.yahoo.com/news/did-lillys-3-5-billion-100802648.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ec0d7a7c-4fcf-371b-a5c0-16303471a930",
      "content": {
        "id": "ec0d7a7c-4fcf-371b-a5c0-16303471a930",
        "contentType": "STORY",
        "title": "Did Lilly's $3.5 Billion Retatrutide Plant Just Recast Eli Lilly's (LLY) Obesity Investment Narrative?",
        "description": "",
        "summary": "Eli Lilly and Company recently announced plans to invest more than US$3.50 billion in a new Lehigh Valley, Pennsylvania manufacturing facility that will produce next-generation injectable weight-loss medicines, including the investigational therapy retatrutide, with operations targeted for 2031. By pairing this build-out with advanced AI-enabled manufacturing and a growing network of U.S. plants, Lilly is signaling a long-term commitment to scaling obesity treatments and reinforcing domestic...",
        "pubDate": "2026-02-02T10:08:02Z",
        "displayTime": "2026-02-02T10:08:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/did-lillys-3-5-billion-100802648.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-lillys-3-5-billion-100802648.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T11:07:42+00:00",
    "headline": "Analysis-Obesity market sales potential tightens as Novo and Lilly enter new era",
    "summary": "LONDON, Feb 2 (Reuters) - The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market.",
    "url": "https://finance.yahoo.com/news/analysis-obesity-market-sales-potential-110742804.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "ca6025b6-efba-3b4d-ae76-a684b7514ad7",
      "content": {
        "id": "ca6025b6-efba-3b4d-ae76-a684b7514ad7",
        "contentType": "STORY",
        "title": "Analysis-Obesity market sales potential tightens as Novo and Lilly enter new era",
        "description": "",
        "summary": "LONDON, Feb 2 (Reuters) - The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market.",
        "pubDate": "2026-02-02T11:07:42Z",
        "displayTime": "2026-02-02T11:07:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/a6e293b9491d31650b4d2d68a0721002",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qjbrrgSIjz2nYIx_D5XDEA--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a6e293b9491d31650b4d2d68a0721002.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yRfA3bpG4Rg_njU28ZzLQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a6e293b9491d31650b4d2d68a0721002.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-obesity-market-sales-potential-110742804.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-obesity-market-sales-potential-110742804.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T12:35:44+00:00",
    "headline": "Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site",
    "summary": "Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-selects-pennsylvania-for-3-5bn-obesity-drugs-manufacturing-site/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "77cb2b84-cd25-337f-9e4b-72b1fe82bdf9",
      "content": {
        "id": "77cb2b84-cd25-337f-9e4b-72b1fe82bdf9",
        "contentType": "STORY",
        "title": "Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site",
        "description": "",
        "summary": "Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.",
        "pubDate": "2026-02-02T12:35:44Z",
        "displayTime": "2026-02-02T12:35:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/037a3bc8b63e3b97dc1d6bb8ab68b022",
          "originalWidth": 800,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1xLa9oylypySQ7qMCvjiUQ--~B/aD00MDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/037a3bc8b63e3b97dc1d6bb8ab68b022.cf.webp",
              "width": 800,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zSmY98O.8HEiWyCoKLto0A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/037a3bc8b63e3b97dc1d6bb8ab68b022.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-selects-pennsylvania-for-3-5bn-obesity-drugs-manufacturing-site/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-selects-pennsylvania-3-123544107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T11:55:15+00:00",
    "headline": "Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 7 Best Low-Risk Dividend Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. According to a January 29 report by Reuters, Eli Lilly and Company (NYSE:LLY) is teaming up with Repertoire […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-forms-115515291.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "15348a66-8637-329e-aede-384a8e78f091",
      "content": {
        "id": "15348a66-8637-329e-aede-384a8e78f091",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 7 Best Low-Risk Dividend Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. According to a January 29 report by Reuters, Eli Lilly and Company (NYSE:LLY) is teaming up with Repertoire […]",
        "pubDate": "2026-02-02T11:55:15Z",
        "displayTime": "2026-02-02T11:55:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2c8f851c326321f2c94ddd4776afda17",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYG5Yb2Ryw09lOYtZg2v7Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2c8f851c326321f2c94ddd4776afda17.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NF09K7qUiav0AMXeYxdZeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2c8f851c326321f2c94ddd4776afda17.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-forms-115515291.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-forms-115515291.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T11:46:08+00:00",
    "headline": "Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill",
    "summary": "Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage To Unlock Millions Of Patients In an interview with CNBC, Ricks said that the new policy will allow Medicare beneficiaries to access obesity drugs \"immediately following launch\" of the company's highly anticipated experimental weight-loss drug, Orforglipron. With 20 million to 30 million Medicare p",
    "url": "https://finance.yahoo.com/news/eli-lilly-ceo-says-medicare-114608087.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "ea036e68-2751-3505-b3b6-07b9ed2c0818",
      "content": {
        "id": "ea036e68-2751-3505-b3b6-07b9ed2c0818",
        "contentType": "STORY",
        "title": "Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill",
        "description": "",
        "summary": "Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage To Unlock Millions Of Patients In an interview with CNBC, Ricks said that the new policy will allow Medicare beneficiaries to access obesity drugs \"immediately following launch\" of the company's highly anticipated experimental weight-loss drug, Orforglipron. With 20 million to 30 million Medicare p",
        "pubDate": "2026-02-02T11:46:08Z",
        "displayTime": "2026-02-02T11:46:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/f9edfe6d5c579be6a19bd07039a49997",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MUQS3jRHx.W09ycOZ7EI3g--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/f9edfe6d5c579be6a19bd07039a49997.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/91uhlDyeax2_rqn99HFhDQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/f9edfe6d5c579be6a19bd07039a49997.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-ceo-says-medicare-114608087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-ceo-says-medicare-114608087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T14:17:50+00:00",
    "headline": "Obesity market sales potential tightens as Novo and Lilly enter new era",
    "summary": "<body><p>STORY: The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is potentially looking a lot less certain.</p><p>That's as U.S. prices are falling for GLP-1 treatments from Novo Nordisk and Eli Lilly.</p><p>And competition heats up in the cash-pay consumer market.</p><p>Analysts and investors say the fast-changing landscape, which also includes the expected entry of new drugs, has led to a recalculation of what the peak will be.</p><p>And when those heights may be reached.</p><p>One portfolio manager said the “peak has come down a little,\" pointing to pricing in the new consumer market and the launch of generic versions of Novo's Ozempic.</p><p>Unprecedented demand for weight-loss drugs targeting the GLP-1 hormone led analysts to project a market of $150 billion - or even $200 billion - by the early 2030s.</p><p>But for analysts and investors, 2030 forecasts are around 30% lower and that $150 billion target has shifted to 2035 for some.</p><p>Dominant players Novo and Lilly both report fourth-quarter financial results on Wednesday.</p><p>Lilly reached a $1 trillion valuation last year and Novo's new Wegovy weight-loss pill got off to a strong start.</p><p>According to data, Novo's Wegovy injection and pill and Lilly's Zepbound injection prescriptions totalled 730,000 in the week eding January 23rd.</p><p>New Wegovy prescriptions grew 4%, largely due to the new pill, while Zepbound was up 0.9%.</p></body>",
    "url": "https://finance.yahoo.com/video/obesity-market-sales-potential-tightens-141750524.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "56145b57-c5ec-346e-8ee4-1d4d874910e0",
      "content": {
        "id": "56145b57-c5ec-346e-8ee4-1d4d874910e0",
        "contentType": "VIDEO",
        "title": "Obesity market sales potential tightens as Novo and Lilly enter new era",
        "description": "<title><body><p>STORY: The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is potentially looking a lot less certain.</p><p>That's as U.S. prices are falling for GLP-1 treatments from Novo Nordisk and Eli Lilly.</p><p>And competition heats up in the cash-pay consumer market.</p><p>Analysts and investors say the fast-changing landscape, which also includes the expected entry of new drugs, has led to a recalculation of what the peak will be.</p><p>And when those heights may be reached.</p><p>One portfolio manager said the “peak has come down a little,\" pointing to pricing in the new consumer market and the launch of generic versions of Novo's Ozempic.</p><p>Unprecedented demand for weight-loss drugs targeting the GLP-1 hormone led analysts to project a market of $150 billion - or even $200 billion - by the early 2030s.</p><p>But for analysts and investors, 2030 forecasts are around 30% lower and that $150 billion target has shifted to 2035 for some.</p><p>Dominant players Novo and Lilly both report fourth-quarter financial results on Wednesday.</p><p>Lilly reached a $1 trillion valuation last year and Novo's new Wegovy weight-loss pill got off to a strong start.</p><p>According to data, Novo's Wegovy injection and pill and Lilly's Zepbound injection prescriptions totalled 730,000 in the week eding January 23rd.</p><p>New Wegovy prescriptions grew 4%, largely due to the new pill, while Zepbound was up 0.9%.</p></body></title>",
        "summary": "<body><p>STORY: The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is potentially looking a lot less certain.</p><p>That's as U.S. prices are falling for GLP-1 treatments from Novo Nordisk and Eli Lilly.</p><p>And competition heats up in the cash-pay consumer market.</p><p>Analysts and investors say the fast-changing landscape, which also includes the expected entry of new drugs, has led to a recalculation of what the peak will be.</p><p>And when those heights may be reached.</p><p>One portfolio manager said the “peak has come down a little,\" pointing to pricing in the new consumer market and the launch of generic versions of Novo's Ozempic.</p><p>Unprecedented demand for weight-loss drugs targeting the GLP-1 hormone led analysts to project a market of $150 billion - or even $200 billion - by the early 2030s.</p><p>But for analysts and investors, 2030 forecasts are around 30% lower and that $150 billion target has shifted to 2035 for some.</p><p>Dominant players Novo and Lilly both report fourth-quarter financial results on Wednesday.</p><p>Lilly reached a $1 trillion valuation last year and Novo's new Wegovy weight-loss pill got off to a strong start.</p><p>According to data, Novo's Wegovy injection and pill and Lilly's Zepbound injection prescriptions totalled 730,000 in the week eding January 23rd.</p><p>New Wegovy prescriptions grew 4%, largely due to the new pill, while Zepbound was up 0.9%.</p></body>",
        "pubDate": "2026-02-02T14:17:50Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/h1YnzFVCw1VXEJYJ9cA67g--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2af03cb7-89fd-4b9a-97f9-348f6cf9a4d4/main/1280x720/54s250ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aX38lFsSE227360S.82.mA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2af03cb7-89fd-4b9a-97f9-348f6cf9a4d4/main/1280x720/54s250ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b5HcwO1HgCv8MTPidJxZzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/2af03cb7-89fd-4b9a-97f9-348f6cf9a4d4/main/1280x720/54s250ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/obesity-market-sales-potential-tightens-141750524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/obesity-market-sales-potential-tightens-141750524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-02T12:15:00+00:00",
    "headline": "Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings?",
    "summary": "LLY heads into Q4 earnings with GLP-1 demand from Mounjaro and Zepbound, as pricing pressure and new oral Wegovy competition loom.",
    "url": "https://finance.yahoo.com/news/investors-buy-sell-hold-lilly-121500705.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9f5a8b40-45bc-3566-8793-978c2e41c242",
      "content": {
        "id": "9f5a8b40-45bc-3566-8793-978c2e41c242",
        "contentType": "STORY",
        "title": "Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings?",
        "description": "",
        "summary": "LLY heads into Q4 earnings with GLP-1 demand from Mounjaro and Zepbound, as pricing pressure and new oral Wegovy competition loom.",
        "pubDate": "2026-02-02T12:15:00Z",
        "displayTime": "2026-02-02T12:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-buy-sell-hold-lilly-121500705.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-buy-sell-hold-lilly-121500705.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]